Cargando…

SARS-CoV-2/COVID-19 – Epidemiologie und Prävention

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly r...

Descripción completa

Detalles Bibliográficos
Autores principales: Salzberger, Bernd, Buder, Felix, Lampl, Benedikt, Ehrenstein, Boris, Hitzenbichler, Florian, Holzmann, Thomas, Schmidt, Barbara, Hanses, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736674/
https://www.ncbi.nlm.nih.gov/pubmed/33343742
http://dx.doi.org/10.1007/s11560-020-00472-0
_version_ 1783622813416947712
author Salzberger, Bernd
Buder, Felix
Lampl, Benedikt
Ehrenstein, Boris
Hitzenbichler, Florian
Holzmann, Thomas
Schmidt, Barbara
Hanses, Frank
author_facet Salzberger, Bernd
Buder, Felix
Lampl, Benedikt
Ehrenstein, Boris
Hitzenbichler, Florian
Holzmann, Thomas
Schmidt, Barbara
Hanses, Frank
author_sort Salzberger, Bernd
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly replicates in the upper and lower respiratory tracts and is particularly transmitted by droplets and aerosols. The estimate for the basic reproduction number (R(0)) is between 2 and 3 and the median incubation period is 6 days (range 2–14 days). As with the related SARS-CoV and Middle East respiratory syndrome (MERS-CoV), superspreading events play an important role in the dissemination. A high proportion of infections are uncomplicated but moderate or severe courses develop in 5–10% of infected persons. Pneumonia, cardiac involvement and thromboembolisms are the most frequent manifestations leading to hospitalization. Risk factors for a complicated course are high age, hypertension, diabetes mellitus and chronic cardiovascular and pulmonary diseases as well as immunodeficiency. Currently, the estimation for the infection fatality rate (IFR) is between 0.5% and 1% across all age groups. Outbreaks were limited in many regions with bundles of various measures for reduction of social contacts. The incidence for the first wave in Germany can be estimated as 0.4–1.8% and excess mortality could not be observed.
format Online
Article
Text
id pubmed-7736674
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-77366742020-12-15 SARS-CoV-2/COVID-19 – Epidemiologie und Prävention Salzberger, Bernd Buder, Felix Lampl, Benedikt Ehrenstein, Boris Hitzenbichler, Florian Holzmann, Thomas Schmidt, Barbara Hanses, Frank Nephrologe Leitthema Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread globally since December 2019. A first wave is visible up to the end of June 2020 in many regions. This article presents a review of the current knowledge on the epidemiology and prevention. The SARS-CoV‑2 predominantly replicates in the upper and lower respiratory tracts and is particularly transmitted by droplets and aerosols. The estimate for the basic reproduction number (R(0)) is between 2 and 3 and the median incubation period is 6 days (range 2–14 days). As with the related SARS-CoV and Middle East respiratory syndrome (MERS-CoV), superspreading events play an important role in the dissemination. A high proportion of infections are uncomplicated but moderate or severe courses develop in 5–10% of infected persons. Pneumonia, cardiac involvement and thromboembolisms are the most frequent manifestations leading to hospitalization. Risk factors for a complicated course are high age, hypertension, diabetes mellitus and chronic cardiovascular and pulmonary diseases as well as immunodeficiency. Currently, the estimation for the infection fatality rate (IFR) is between 0.5% and 1% across all age groups. Outbreaks were limited in many regions with bundles of various measures for reduction of social contacts. The incidence for the first wave in Germany can be estimated as 0.4–1.8% and excess mortality could not be observed. Springer Medizin 2020-12-15 2021 /pmc/articles/PMC7736674/ /pubmed/33343742 http://dx.doi.org/10.1007/s11560-020-00472-0 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leitthema
Salzberger, Bernd
Buder, Felix
Lampl, Benedikt
Ehrenstein, Boris
Hitzenbichler, Florian
Holzmann, Thomas
Schmidt, Barbara
Hanses, Frank
SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
title SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
title_full SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
title_fullStr SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
title_full_unstemmed SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
title_short SARS-CoV-2/COVID-19 – Epidemiologie und Prävention
title_sort sars-cov-2/covid-19 – epidemiologie und prävention
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736674/
https://www.ncbi.nlm.nih.gov/pubmed/33343742
http://dx.doi.org/10.1007/s11560-020-00472-0
work_keys_str_mv AT salzbergerbernd sarscov2covid19epidemiologieundpravention
AT buderfelix sarscov2covid19epidemiologieundpravention
AT lamplbenedikt sarscov2covid19epidemiologieundpravention
AT ehrensteinboris sarscov2covid19epidemiologieundpravention
AT hitzenbichlerflorian sarscov2covid19epidemiologieundpravention
AT holzmannthomas sarscov2covid19epidemiologieundpravention
AT schmidtbarbara sarscov2covid19epidemiologieundpravention
AT hansesfrank sarscov2covid19epidemiologieundpravention